Indegene Ltd
Indegene Ltd (INDGN) is scheduled to report results on 29 Oct 2026. Indegene Ltd last reported results for the quarter ended Jun 2026, with sales of ₹1,063 crore and net profit of ₹116 crore. The stock last traded at ₹594, a market capitalisation of ₹14,301 crore, on a P/E of 34.3. Over the past 52 weeks the stock has ranged between ₹414 and ₹627. Figures are as of 6 Oct 2026 and are not real time.
Indegene Ltd share price and key metrics
- Current price
- ₹594
- Market cap
- ₹14,301 cr
- Stock P/E
- 34.3
- Book value
- ₹130
- ROE
- 14.4%
- ROCE
- 18.8%
- Dividend yield
- 0.38%
- 52w high / low
- 627/414
Metrics as of 6 Oct 2026. Not real time.
Track Indegene Ltd
Cruxal reads every Indegene Ltd filing as it lands, scores what it means for the stock, and emails you the ones that matter. Free to start.
Indegene Ltd growth and returns
- 10 Years
- %
- 5 Years
- 29%
- 3 Years
- 15%
- TTM
- 30%
- 10 Years
- %
- 5 Years
- 23%
- 3 Years
- 16%
- TTM
- -4%
- 10 Years
- %
- 5 Years
- %
- 3 Years
- %
- 1 Year
- 5%
- 10 Years
- %
- 5 Years
- 21%
- 3 Years
- 19%
- Last Year
- 14%
Indegene Ltd quarterly results
In the quarter ended Jun 2026, sales were ₹1,063 cr, up 39.7% from ₹761 cr a year earlier. Net profit was ₹116 cr, up 0.0% year on year.
| ₹ crore | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 687 | 720 | 756 | 761 | 804 | 942 | 1,003 | 1,063 |
| Expenses | 561 | 589 | 608 | 606 | 664 | 783 | 840 | 889 |
| Operating profit | 126 | 132 | 148 | 155 | 141 | 160 | 164 | 174 |
| OPM % | 18% | 18% | 20% | 20% | 17% | 17% | 16% | 16% |
| Other income | 21 | 38 | 26 | 22 | 20 | 19 | -10 | 29 |
| Interest | 4 | 3 | 3 | 4 | 4 | 5 | 7 | 6 |
| Depreciation | 19 | 20 | 21 | 22 | 23 | 40 | 42 | 44 |
| Profit before tax | 124 | 146 | 149 | 152 | 133 | 135 | 105 | 153 |
| Tax % | 26% | 25% | 21% | 23% | 23% | 24% | 24% | 24% |
| Net profit | 92 | 110 | 118 | 116 | 102 | 103 | 80 | 116 |
| EPS (₹) | 3.83 | 4.58 | 4.90 | 4.85 | 4.25 | 4.28 | 3.31 | 4.82 |
Consolidated figures as reported by the company. Percentages are as published; totals may not sum exactly.
Indegene Ltd annual results
| ₹ crore | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|
| Sales | 553 | 643 | 966 | 1,665 | 2,306 | 2,590 | 2,839 | 3,510 | 3,813 |
| Operating profit | 42 | 144 | 230 | 287 | 396 | 505 | 548 | 619 | 638 |
| OPM % | 8% | 22% | 24% | 17% | 17% | 20% | 19% | 18% | 17% |
| Net profit | 14 | -12 | 149 | 163 | 266 | 337 | 407 | 401 | 401 |
| EPS (₹) | 89.98 | -40.20 | 951.96 | 937.73 | 11.99 | 15.14 | 16.95 | 16.65 | 16.66 |
TTM is the trailing twelve months to the most recent quarter.
Indegene Ltd balance sheet
| ₹ crore | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| Equity capital | 0.31 | 0.31 | 0.31 | 0.35 | 44 | 44 | 48 | 48 |
| Reserves | 73 | -105 | 324 | 764 | 1,020 | 1,385 | 2,568 | 3,091 |
| Borrowings | 147 | 483 | 51 | 66 | 502 | 490 | 102 | 144 |
| Other liabilities | 108 | 222 | 220 | 524 | 638 | 627 | 609 | 1,337 |
| Total liabilities | 329 | 600 | 596 | 1,353 | 2,204 | 2,546 | 3,326 | 4,620 |
| Fixed assets | 104 | 119 | 86 | 138 | 664 | 646 | 678 | 1,812 |
| CWIP | 0 | 0 | 0 | 0 | 0 | 0 | 4 | 12 |
| Investments | 0 | 13 | 0 | 120 | 614 | 796 | 1,290 | 1,100 |
| Other assets | 225 | 468 | 510 | 1,096 | 926 | 1,103 | 1,355 | 1,697 |
| Total assets | 329 | 600 | 596 | 1,353 | 2,204 | 2,546 | 3,326 | 4,620 |
As reported by the company. Total assets equal total liabilities by construction.
Indegene Ltd cash flow
| ₹ crore | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| Cash from operations | 65 | 22 | 172 | 297 | 130 | 508 | 442 | 651 |
| Cash from investing | -18 | -16 | -81 | -158 | -896 | -326 | -677 | -508 |
| Cash from financing | -21 | 136 | -132 | 233 | 333 | -66 | 288 | -83 |
| Net cash flow | 25 | 143 | -40 | 373 | -433 | 115 | 52 | 60 |
| Free cash flow | 48 | 16 | 151 | 272 | 111 | 497 | 412 | 606 |
| CFO / operating profit | 196% | 34% | 96% | 128% | 60% | 125% | 110% | 129% |
Negative figures are outflows. CFO / operating profit is a ratio, not an amount.
Indegene Ltd operating ratios
| Per year | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| ROCE % | — | 37% | 55% | 46% | 33% | 29% | 25% | 19% |
| Debtor days | 60 | 127 | 108 | 97 | 102 | 91 | 97 | 102 |
| Cash conversion cycle | 60 | 127 | 108 | 97 | 102 | 91 | 97 | 102 |
| Working capital days | -7 | -5 | 45 | 11 | 41 | 27 | 39 | 5 |
Ratios as computed by the source from the reported statements. Rows a company does not report are omitted.
Indegene Ltd shareholding pattern
| % held | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| FIIs | 4.82% | 5.03% | 5.24% | 10.04% | 11.30% | 11.48% | 10.27% | 9.92% |
| DIIs | 3.17% | 3.99% | 4.96% | 7.20% | 6.95% | 8.06% | 8.29% | 8.74% |
| Public | 92.01% | 91.01% | 89.80% | 82.75% | 81.74% | 80.44% | 81.43% | 81.34% |
| No. of shareholders | 1,51,440 | 1,53,789 | 1,44,708 | 1,51,997 | 1,51,809 | 1,47,182 | 1,42,119 | 1,38,533 |
As disclosed by the company to the exchanges. The last row is a count of shareholders, not a percentage.
When is Indegene Ltd’s next results date?
Indegene Ltd’s next results are scheduled for 29 Oct 2026.
- Board meetingApproval of unaudited financial results and allotment under RSU and ESOP schemes
- Earnings resultsQ2 FY27 Earnings Call
See the full results calendar for every Indian company reporting in the next 30 days.
Indegene Ltd corporate filings
- Certificate under Regulation 74 (5) of SEBI DP Regulations, 2018Company Updatelow impact
- Indegene Ltd Allots ESOP Shares on October 8, 2026Company Updatelow impact
Cruxal's analysis: Indegene Ltd announced the allotment of ESOP shares on October 8, 2026. The company is a…
Read the full analysis - Indegene Ltd releases press statement under Regulation 30, no financial or operational updates providedCompany Updatelow impact
Cruxal's analysis: Indegene Ltd, a small-cap company with a market cap of approximately 14,568 crore, issued…
Read the full analysis - Indegene Limited schedules Q2 FY27 earnings call on 30 October 2026, indicating upcoming financial disclosuresCompany Updatelow impact
Cruxal's analysis: Indegene Limited has announced its Q2 FY27 earnings call scheduled for 30 October 2026 at…
Read the full analysis - Indegene Limited schedules Board Meeting on 29 October 2026 to consider and approve unaudited financial results for Q2 FY2027 (ending 30 September 2026) and allotment under RSU and ESOP schemesBoard Meetinglow impact
Cruxal's analysis: Indegene Limited has announced a scheduled Board meeting on 29 October 2026 to approve…
Read the full analysis - Closure of Trading WindowInsider Trading / SASTlow impact
- Indegene Ltd files routine press release under Regulation 30Company Updatelow impact
Cruxal's analysis: Indegene Ltd has submitted a press release under Regulation 30 of the SEBI (LODR)…
Read the full analysis - Indegene Limited announces internal reorganization of German subsidiaries via mergerCompany Updatelow impact
Cruxal's analysis: Indegene Limited has completed the merger of its indirect wholly owned subsidiaries…
Read the full analysis - Indegene Ltd announces upcoming analyst/investor meetingCompany Updatelow impact
Cruxal's analysis: Indegene Ltd has issued an intimation regarding a scheduled meeting with analysts and…
Read the full analysis - Indegene provides update on material litigation involving US subsidiary under TCPACompany Updatelow impact
Cruxal's analysis: Indegene Ltd has issued a disclosure regarding ongoing material litigation involving its…
Read the full analysis - Indegene Ltd schedules analyst and investor meetingCompany Updatelow impact
Cruxal's analysis: Indegene Ltd has issued an intimation regarding a scheduled meeting with analysts and…
Read the full analysis - Indegene provides update on material litigation involving subsidiary Indegene, Inc. under TCPACompany Updatelow impact
Cruxal's analysis: Indegene Ltd has issued a regulatory update regarding ongoing material litigation…
Read the full analysis - Indegene Limited AGM Transcript Highlights Strategic Focus on AI-Led Growth and Margin NormalizationAGM/EGMmedium impact
Cruxal's analysis: Indegene Limited's 28th AGM transcript outlines a strategic pivot toward AI-embedded…
Read the full analysis - Indegene Limited formalizes appointment of Ms. Jill Mary De Simone as Independent DirectorCompany Updatelow impact
Cruxal's analysis: Indegene Limited has confirmed the shareholder approval for the appointment of Ms. Jill…
Read the full analysis - Indegene Limited concludes 28th Annual General Meeting with all resolutions passedAGM/EGMlow impact
Cruxal's analysis: Indegene Limited has successfully concluded its 28th Annual General Meeting held on…
Read the full analysis - Indegene Ltd announces intimation of upcoming analyst/investor meetingCompany Updatelow impact
Cruxal's analysis: Indegene Ltd has filed an intimation regarding a scheduled meeting with analysts and…
Read the full analysis - Indegene Limited concludes 28th AGM; declares final dividend of INR 2.25 per shareAGM/EGMlow impact
Cruxal's analysis: Indegene Limited has successfully concluded its 28th Annual General Meeting held on…
Read the full analysis - Indegene Ltd announces intimation of upcoming analyst/investor meetingCompany Updatelow impact
Cruxal's analysis: Indegene Ltd has filed an intimation regarding a scheduled meeting with analysts and…
Read the full analysis - Indegene Ltd schedules analyst/investor meeting for August 12, 2026Company Updatelow impact
Cruxal's analysis: Indegene Ltd has issued an intimation regarding a scheduled meeting with analysts and…
Read the full analysis - BPC Genesis Fund I-A SPV Limited exits entire 2.99% stake in Indegene Limited via open market saleInsider Trading / SASTmedium impact
Cruxal's analysis: Indegene Limited has witnessed a complete exit by BPC Genesis Fund I-A SPV Limited, which…
Read the full analysis
This page shows filings on a one-hour delay. Sign in to see them as they land, with Cruxal's analysis of what each one means.
Cruxal publishes market data and coverage for information only. Nothing here is investment advice.